Samuel D Banister, Kaavya Krishna Kumar, Vineet Kumar, Brian K Kobilka, Sanjay V Malhotra
{"title":"Selective modulation of the cannabinoid type 1 (CB<sub>1</sub>) receptor as an emerging platform for the treatment of neuropathic pain.","authors":"Samuel D Banister, Kaavya Krishna Kumar, Vineet Kumar, Brian K Kobilka, Sanjay V Malhotra","doi":"10.1039/c8md00595h","DOIUrl":null,"url":null,"abstract":"<p><p>Neuropathic pain is caused by a lesion or dysfunction in the nervous system, and it may arise from illness, be drug-induced or caused by toxin exposure. Since the discovery of two G-protein-coupled cannabinoid receptors (CB<sub>1</sub> and CB<sub>2</sub>) nearly three decades ago, there has been a rapid expansion in our understanding of cannabinoid pharmacology. This is currently one of the most active fields of neuropharmacology, and interest has emerged in developing cannabinoids and other small molecule modulators of CB<sub>1</sub> and CB<sub>2</sub> as therapeutics for neuropathic pain. This short review article provides an overview of the chemotypes currently under investigation for the development of novel neuropathic pain treatments targeting CB<sub>1</sub> receptors.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":"10 5","pages":"647-659"},"PeriodicalIF":3.5970,"publicationDate":"2019-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533890/pdf/MD-010-C8MD00595H.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1039/c8md00595h","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/5/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Neuropathic pain is caused by a lesion or dysfunction in the nervous system, and it may arise from illness, be drug-induced or caused by toxin exposure. Since the discovery of two G-protein-coupled cannabinoid receptors (CB1 and CB2) nearly three decades ago, there has been a rapid expansion in our understanding of cannabinoid pharmacology. This is currently one of the most active fields of neuropharmacology, and interest has emerged in developing cannabinoids and other small molecule modulators of CB1 and CB2 as therapeutics for neuropathic pain. This short review article provides an overview of the chemotypes currently under investigation for the development of novel neuropathic pain treatments targeting CB1 receptors.
期刊介绍：
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
